Inhibrx Data di Ex-dividendi
Cos'è Data di Ex-dividendi di Inhibrx?
Data di Ex-dividendi di Inhibrx, Inc. è N/A
Qual è la definizione di Data di Ex-dividendi?
La data di stacco cedola è la data limite prima della quale il pagamento dei dividendi dopo una vendita appartiene al nuovo proprietario anziché al venditore.
The ex-dividend date or reinvestment date is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings. If a sale is before this date, the dividend belongs to the new owner; if on or after the date, the seller is entitled to the dividend. If a stock is purchased on its ex-dividend date or after, the buyer will not receive the next dividend payment. Instead, the seller gets the dividend. If a stock is purchased before the ex-dividend date, the buyer gets the dividend.
Cosa fa Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.